LSO-028 Predictors of de novo renal flares in systemic lupus erythematosus – time to revisit belimumab dose for extra-renal disease? Results from five phase III clinical trials of belimumab

• Brad Rovin,
• Frederic Houssiau,
• Christopher Sjöwall,
• Ioannis Parodis,
• Julius Lindblom,
• Nurşen Çetrez,
• Leonardo Palazzo,
• Henri Ala

Affiliations

Brad Rovin

5Department of Internal Medicine, The Ohio State University College of Medicine, USA

Frederic Houssiau

3Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain and Service de Rhumatologie, Cliniques Universitaires Saint-Luc, Belgium

Christopher Sjöwall

4Department of Biomedical and Clinical Sciences, Linköping University, Sweden

Ioannis Parodis

1Department of Medicine Solna, Karolinska Institutet, Sweden

Julius Lindblom

1Department of medicine Solna, Karolinska Institutet, Sweden

Nurşen Çetrez

1Department of Medicine Solna, Karolinska Institutet, Sweden

Leonardo Palazzo

1Department of Medicine Solna, Karolinska Institutet, Sweden

Henri Ala

1Department of Medicine Solna, Karolinska Institutet, Sweden